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ABSTRACT
Biomarkers are becoming an essential part of clinical development, not least because they offer a faster alternative to the conventional drug 
development approach and the promise of safer drugs, in greater numbers, approved more quickly. Many of the failures happen late in clinical trials, 
with the consequence that expenditure in clinical drug development – already a mammoth effort requiring a huge amount of money, time, and patient 
is increasing. The ultimate vision is to have access to therapeutic fields, a better understanding of pathophysiology of diseases, thereby uncovering 
potential drug targets and biomarkers in the disease pathway. By finding molecular biomarkers of the disease, diagnosis could be improved and could 
reveal new information about the disease, by which a better chance for developing drugs is possible. Biomarkers can also reflect the entire spectrum 
of disease from the earliest manifestations to the terminal stages. In this present review, biomarkers of various diseases were enlisted to highlight 
the overabundance of information necessary for clinicians and scientists to have a thorough understanding of biomarkers and its ability to improve 
treatment and reduce health-care costs which are potentially greater than in any other area of medical research.
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INTRODUCTION
In 1998, the National Institutes of Health Biomarkers Definitions 
Working Group defined a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [1,2]. A joint venture on chemical safety, the 
International Programmed on Chemical Safety, led by the World Health 
Organization (WHO) and in coordination with the United Nations and 
the International Labor Organization, has defined a biomarker as “any 
substance, structure, or process that can be measured in the body 
or its products and influence or predict the incidence of outcome or 
disease” [3]. The WHO also stated that a true definition of biomarkers 
includes “almost any measurement reflecting an interaction between 
a biological system and a potential hazard, which may be chemical, 
physical, and biological. The measured response may be functional 
and physiological, biochemical at the cellular level, or a molecular 
interaction” [4]. Examples of biomarkers include everything from 
pulse and blood pressure through basic chemistries to more complex 
laboratory tests of blood and other tissues [5,6].
Disease-related biomarkers give an indication of whether there is a 
threat of disease (risk indicator or predictive biomarkers) if a disease 
already exists (diagnostic biomarkers), or how such a disease may 
develop in an individual case (prognostic biomarker). Drug-related 
biomarkers indicate whether a drug will be effective in a specific patient 
and how the patient’s body will process it.
Biomarkers a measure of a normal biological process in the body, a 
pathological process, or the response of the body to therapy – may offer 
information about the mechanism of action of the drug, its efficacy, 
its safety, and metabolite profile. Because biomarkers can predict 
drug efficacy more quickly than conventional clinical end-points, they 
hold the potential to substantially accelerate product development in 
certain disease areas. And because they help to identify earlier those 
candidates that are likely to fail, they reduce drug development costs, 
giving life to the concept of “fail early, fail cheap.”
Biomarkers have impacted on internal decision-making, i.e., whether 
to move forward to the next phase of clinical development or not. The 
decision to move to next phase depends not only on biomarker evidence 
alone but also they can offer strong supporting evidence, and in the 
future, it will be the key data in certain programs and offers an objective, 
biological indicator, rather than just seeing whether the patients feel 
better. In the present scenario, there is no possibility of developing a 
new drug without simultaneously looking for biomarkers for efficacy, 
safety, and to measure the pharmacodynamics of the drug. Mechanistic 
or target biomarkers can be used in the pre-clinical or phase I trials 
to measure the pharmacological effect of the drug, i.e., whether the 
drug interacts with its receptor, enzyme, or protein target, whether it 
is distributed to the site where it needs to act, whether there is some 
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Fig. 1: Classification of biomarkers
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Table 1: Techniques available for biomarker development
Technology Method Objective Tissue
Genomics SNP genotyping, positional cloning/microsatellites, 
expression analyses
Identify susceptibility or disease-modifying 
gene
Fine mapping/sequencing of disease loci




Proteomics 2DGE, MS, LC-MS, GC-MS, MS-MS, MALDI–TOF MS Identification of low – abundance proteins, 
their subcellular location, post-translational 
modification, interactions among proteins
Urine, blood, 
saliva, tissues
Metabolomics NMR spectroscopy, MS, infrared spectroscopy Small molecule identification and 
characterization
As above
Pharmacogenetics SNP genotyping Relate genetic makeup to drug response Nucleated cells
Integratomics All of the above Use of high throughput technology to produce 
an integrated picture at the DNA, RNA, 
protein, tissue, and pharmacological levels
All of the above
Bioinformatics BLAST, hierarchical clustering, SOM Link microarray data to biological pathways Data from various 
techniques
Molecular imaging [13] CT, MRI, PET, SPECT, biophotonic imaging Noninvasively identify and quantify the 
causative molecular constituents of diseased 
tissues in time and space
Patients
MRI: Magnetic resonance imaging, CT: Computed tomography, PET: Positron emission tomography, SPECT: Single-photon emission computed tomography, 
SNP: Single nucleotide polymorphism, MS: Mass spectroscopy, NMR: Nuclear magnetic resonance, 2DGE: 2D gel electrophoresis, TOF: Time-of-flight, LC-MS: Liquid 
chromatograph-mass spectroscopy, GC-MS: Gas chromatography-mass spectrometry, SOM: Self-organizing maps
Table 2: Five phases of biomarker development















Phase 5 disease 
control
Objective Target biomarker 
identification, feasibility
Study assay in people 














Design Cross-sectional Cross-sectional Case-control Prospective RCT
Sample size Small Small Modest Medium Large
Validity Content and construct 
validity
Criterion validity Predictive validity Efficacy of strategy Effectiveness






ROC analyses No needed to 
screen treat
RCT: Randomized controlled trial, ROC: Receiver operating characteristic
Table 3: Breaking the barriers to biomarker discovery
Barrier to cancer biomarker progress [17,18] Emerging successful strategies to break the barrier
Failure to mechanistically tie a blood biomarker to the tumor itself Discovery of the biomarker across a series of experimental animal 
tumor models
Mechanistically showing a role in tumor genesis or a change after 
therapy
Validation of the same marker using human samples
Improper sample handling and tracking; inadequate tissue fixation and 
body fluid sample preservation that generates bias, false positives, and 
false negatives
Preservation technologies for tissue and body fluid sample collection
Uniform protocols for the collection of tissues and body fluids
Molecular measures to verify the reservation of a biological sample
Lack of independent blinded clinical validation with proper controls 
for specificity and noncancer diseases
Inclusion of independent epidemiologically credentialed and matched 
cohorts with inflammatory disease, infectious disease, and benign 
tumors
Low analytical sensitivity of mass spectrometry-based detection 
systems that prevent the detection/identification and measurement 
of low abundance (<ng/nl) biomarkers emanating from early stage 
cancer
Nanotechnology-based methods for biomarker capture, preservation, 
and exclusion of unwanted high-abundance proteins such as albumin 
can amplify mass spectrometry sensitivity 1000
form of downstream pharmacology, and the dose ranges, in which the 
drug is pharmacologically active. Hence, these types of biomarkers 
can be used to drive critical go/no – go decisions in drug development 
(Tables 1 and 2, Figs. 1-4).
At the onset of cancer, a selective protein or gene-based biomarker 
gets elevated or modified in body fluids or tissues. Early diagnosis 
of these markers can greatly improve the survival rate or facilitate 
effective treatment with different modalities. Although the 
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Table 4: Biomarker of cancer disease and their characteristics with examples
Cancer Markers Characteristics Typical 
sample
Prostate PSA, total and free High sensitivity in all stages; also elevated from some 
non-cancer causes
Blood [19]
PSMA Levels tend to increase with age Blood
Breast CA 15-3, 27, 29 Elevated in benign breast conditions. Either CA 15-3 or CA 27, 
29 could be used as marker
Blood [20,21]




Her-2/neu Only 20~30% of patients are positive to Her-2 oncogene that 
is present in multiple copies
Tissue [23]
Lung (non-small cell) CEA Used in combination with NSA to increase specificity, used also 
for colon cancer detection
Blood [24]
Lung (small cell) NSE Better sensitivity toward specific types of lung Caner Blood [25]
Bladder NMP-22, BTA NMP-22 assays tend to have greater sensitivity than BTA 
assays
Urine [26]
Pancreatic BTA Composed of basement membrane complexes Urine [27]
CA 19-9 Elevated also in inflammatory bowel disease, sometimes used 
as colorectal cancer biomarker
Blood [28]
Epithelial ovarian cancer (90% of all 
ovarian cancer)
CA 125 High sensitivity in advanced stage; also elevated with 
endometriosis, some other diseases and benign conditions
Blood [29]
Germ cell cancer of ovaries CA 72-4 No evidence that this biomarker is better than CA-125 but may 
be useful when used in combination
Blood [30]
AFP Also elevated during pregnancy and liver cancer Blood [31]
Multiple myeloma and lymphomas B2M Present in many other conditions, including prostate cancer 




Overproduction of an immunoglobulin or antibody, usually 
detected by protein electrophoresis
Blood, 
Urine [33]
Metastatic melanoma S100B Subunit of the S100 protein family Serum [34]
TA-90 Could be used to monitor patients with high risks of 
developing the disease
Serum [35]
Thyroid Thyroglobulin Principal iodoprotein of the thyroid gland Serum, 
Tissue [36]
Thyroid medullary carcinoma Calcitonin Secreted mainly by parafollicular C cells Blood, 
Serum [37]
Testicular hCG May regulate vascular neoformation through VEGF Serum [38]
WM Monoclonal 
immunoglobulin M
The larger size and increased concentration of the monoclonal 




Lymphomas B2M Present in many other conditions, including prostate cancer 
and renal cell carcinoma
Serum [40]
Lung (non small cell), epithelial, 
colorectal, head and neck, 
pancreatic, or breast
EGFR (Her-1) Binding of the protein to a ligand induces receptor 
dimerization and tyrosine autophosphorylation and leads to 
cell proliferation
Tissue [41]
Colorectal, lung, breast, pancreatic, 
and bladder
CEA Subtle posttranslational modifications might create differences 
between tumor CEA and normal CEA
Serum [42]
T-ALL PTK7 Membrane-bound surface protein of whole cells, and can be 
used to detect circulating tumor cells as targets
Blood [43]
PSA: Prostate-specific antigen, PSMA: Prostate-specific membrane antigen, CA 15-3, 27, 29: Cancer antigen 15-3, 27, 29, CEA: Carcinoembryonic antigen, 
NSE: Neuron-specific enolase, NMP: Matritech’s nuclear matrix protein, BTA: Bladder tumor antigen, CA 19-9: Carbohydrate antigen 19-9, CA 125: Cancer antigen 125, 
CA 72-4: Cancer antigen 72-4, AFP: Alpha-fetoprotein, B2M: Beta-2 microglobulin, TA-90: Tumor-associated glycoprotein antigen, hCG: Human chorionic gonadotropin, 
VEGF: Vascular endothelial growth factor, WM: Waldenstrom’s macroglobulinemia, T-ALL: T-cell acute lymphoblastic leukemia, EGFR: Epidermal growth factor receptor
sophisticated imaging technologies such as magnetic resonance 
imaging, positron emission tomography, and computed tomography 
have the impact of nanotechnology on their improved performance, 
they are however unsuitable for the early detection of cancer 
biomarkers or their quantification. Other approaches for cancer 
diagnosis based on cell morphology and microscopy (biopsies) are 
too not conclusive for early diagnosis of cancer. The only hope for 
early diagnosis of cancer in the near future is by the detection of 
cancer biomarkers using immunoassays/sensors that are reformed 
by Nanotechnology. Attractive properties of nanoparticles have 
miraculously lifted up the design, fabrication, and sensitivity and 
multiplexing of these immunoassays/sensors in biomarker detection 
(Tables 3-7).
CONCLUSION
Biomarkers are biological molecules wit physiological characteristics 
that are more closely linked to the underlying causes of health or 





Based on a variety of symptoms which are giving subjective description 
and uncertain relationship to the disease state are misleading. 
Biomarkers give doctors a more objective and quantifiable basis for 
clinical decision-making.
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Name of disease Effects Risk 
score (%)
Biomarker
Homozygous familial hypercholesterolemia Premature cardiovascular morbidity and 
mortality
10-20 TC, LDL cholesterol [44]
Hypertriglyceridemia/hypertriglyceridemia Elevated levels of Lp(a) 20 Lipid profile [45]
Chronic kidney disease Elevated levels of Lp(a) 10 Lipid profile [46]
Cholelithiasis Gallstone formation due to cholesterol 
and salts
20 LDL cholesterol and small dense
LDL particles [47]
Hypercholesterolemia Very high CVD risks 20 LDL cholesterol and small dense
LDL particles [48]
Atherosclerosis Arterial obstruction, chest pain 20-25 ABCA1 
Efflux
PUFA and carbohydrates, serum 
γ-glutamyl transferase activity, 
blood genomic profiling, and α4β7 
integrin [49]
Coronary heart disease Monocytosis, high diabetics, 
hypertension, and chronic kidney 
diseases
20 Impaired sterol efflux, efflux capacity 
of HDL, myeloperoxidase increasing 
circulating HDL [50]
Hyperglycemia or type 1 diabetes CVD and mortality 25 TC, TG, HDL, LDL, and 
anthropometric and biochemical 
parameters [51]
Dyslipidemia Hypoperfusion, high inflammation, and 
low BP
10 TC, TG, HDL, LDL, and 
anthropometric and biochemical 
parameters [52]
Atherosclerotic peripheral arterial disease Prevalent, morbid, and mortal diseases 20 shortening 
of lumen
LDL cholesterol [53]
IHD Endothelial dysfunction, vascular 
inflammation
10-20 Lipids, cholesterol, calcium, and 
cellular debris [54]
Diastolic dysfunction and diastolic heart 
failure
Asymptomatic hypertension 20 Myocardial remodeling [55]
Chronic heart failures ADP-induced platelet aggregation, 
triglycerides, end-diastolic volume, 
end-diastolic dimension, and ventricular 
sepal thickness death
15-20 Lipidemic, hemostasiological, and 
hemodynamic indicators, Willebrand 
factor, and D-dimer [56]
Myocardial infarction Very high morbidity, severe pain 20-25 Circulating microRNAs level in 
patients [57]
Lipid stress and storage Influence cholesterol availability in lipid 





Neuronal dysfunction Neuronal cell death and 
neuroinflammatory
10-15 27-hydroxycholesterol, plasma HDL, 
NAEs [59]
Transient global cerebral ischemia Cardiac arrest and cardiovascular 
Problems
5-10 ω-3 PUFAs [60]




Severe effect on BMR and peripheral and 
cardiac circulation
5-10 Altered serum lipid [62]
HDL metabolism disorders Severe inflammation and pain 5-10 LDs [63]
Nephrotic syndrome Renal filtration chocked 5-10 LDL cholesterol, triglycerides, and 
Lp(a) [64]
Fatal myocardial infarction and brain stroke Cardiovascular risks, morbidity, and 
mortality in elderly men
20-25 Fat-specific protein Fsp27, 
FIT proteins, seipin, and 
ADP-ribosylation factor 1-coat 
protein complex I [65]
Systemic lupus erythematosus Problem of PCV and hemoglobin 5 Factors, proteins, ions, and 
stimulators of heart muscles [66]
Acute myocardial infarction Death of part of myocardial muscles, 
central chest pain, and severe crushing
20-25 Serum soluble ST2 and 
interleukin-33 [67]
Hypertension and dyslipidemia, 
hypercholesterolemia
Cardiovascular risk factors 15-20 TC and LDL [68]
5-10 BP and LDL-C, high BMI [69]
SCVRs Tachyarrhythmias, bradyarrhythmias 5 LDL-C, HDL-C, TG, ApoAI, and ApoB 
Lp(a) [70]
AVDs, type 2 diabetes, or metabolic 
syndrome
Increased levels of triglycerides, low 
levels of high-density lipoprotein 
cholesterol, and postprandial lipemia
20-25 MetS [71]
Procardiovascular risks, cardiovascular risks Inflammation, obesity, and thrombosis 5-10 Sedentary behavior, β-trace protein 
from GFR marker [71]
Table 5: Cardiovascular diseases
(Contd...)
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Name of disease Effects Risk 
score (%)
Biomarker
Metabolic lipid disorders Circulatory dysfunctions, high BP, 
peripheral pain, and high or low BMR
5-10 MALDI-MS, imaging, and lipidomics 
for clinical diagnosis, and proteome 
analysis [71]




Endothelial dysfunction, monocyte 
accumulation, endothelial apoptosis, 
and thrombus formation [71]
Low HDL-C syndromes Increased risk of CAD 5 Sphingomyelin phosphodiesterase 1 
and glucocerebrosidase [71]
Hypothyroidism and gall stone Severe pain, inflammation 5 TSH level and sodium and potassium 
salts [71]
Multiple CVDs, diabetes, stroke, and 
recurrent ischemia syndrome
Hepatic inflammation due to common 
carotid intima-media thickness
10-20 Multiple biomarkers, vascular 
imaging [71]
Angina pectoris Obesity, arterial thickness, BMI, and 
respiration rate, and severe chest pain
10-0 Coronary angiography [71]
Antiphospholipid syndrome Venous thrombosis 5 microRNAs [71]
Myocardial infarction PAPP-A in serum 15 Severe blood pressure changes, 
central chest pain, and silent or 
knocking angina [71]
HDL: High-density lipoprotein, TC: Total cholesterol, LDL: Low-density lipoprotein, CVD: Cardiovascular disease, PUFA: Polyunsaturated fat, IHD: Ischemic heart disease, 
TG: Triglyceride, NAEs: N-acylethanolamines, LDs: Lipid droplets, CAD: Coronary artery disease, FIT: Fat storage-inducing transmembrane, BMI: Body mass index, 
PAPP-A: Pregnancy-associated plasma protein-A, TSH: Thyroid-stimulating hormone, BMR: Basal metabolic rate, BP: Blood pressure, GFR: Glomerular filtration rate, 
AVD: Atherosclerotic vascular disease, SCVRs: Spinal cord vascular resistances, MS: Mass spectroscopy, MetS: Metabolic syndrome
Table 5: (Continued)
Table 6:  Hepatocellular carcinoma biomarkers
HCC marker Clinical use
AFP Early diagnosis, monitoring, and recurrence
Lens culinaris agglutinin reactive AFP (AFP-L3%) Early diagnosis and prognosis, vascular invasion
DCP Early diagnosis and prognosis, portal vein invasion and metastasis
Gamma-glutamyl transferase Early diagnosis complementary to other markers
Alpha-l-fucosidase Early diagnosis
Glypican-3 Early diagnosis
Human carbonyl reductase 2 Prognosis
Golgi phosphoprotein 2 Tumor aggressiveness
Transforming growth factor beta Tumor invasiveness
HGF Prognosis and disease recurrence
TGF-b Prognosis invasiveness
Tumor-specific growth factor Diagnosis complementary to other markers
Epidermal growth factor receptor family Early recurrence
Hepatocyte growth factor Metastasis reduced survival
Micro RNAs Tumor spread and survival [72]
AFP: Alpha-fetoprotein, DCP: Des-gamma-carboxy prothrombin, HGF: Hepatocyte growth factor, TGF-b: Transforming growth factor-b, HCC: Hepatocellular carcinoma
Table 7: Analytical method to discover biomarker for Alzheimer’s disease diagnosis
Analytical method Biomarker
ELISA Aβ42,	total	tau,	
phospho – tau – 181 (single)
Multiplex searchlight ELISAs 16 signaling proteins
Filter-based array sandwich ELISA 18 signaling proteins
INNO - BIA AlzBio3 Luminex – based technology (innogenetics) Aβ42,	total	tau,	
phospho – tau – 181 (multiplex)
Tissue array 2325 tissue specimens
Quantitative real-time RT-PCR 33 genes, multiple phosphorylated tau 
epitopes
Liquid chromatography/electrosprayy ionosation MS Aβ	40,	Aβ42
Capillary electrophoresis/MS 1000 polypeptides
Ultrasensitive laser ablation inductively coupled plasma/MS Trace elements and metal ions
Multiplex iTRAQ 1500 CSF proteins
Surface-enhanced laser desorption/ionization or matrix-assisted laser desorption/ionization Several	Aβ	species:
Aβ37,	Aβ36,	Aβ38,	Aβ40
DNA/RNA chips, biochips, gene chips Several thousand genes [73]
MS: Mass spectroscopy, CSF: Cerebrospinal fluid, RT-PCR: Real-time polymerase chain reaction
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Fig. 2: Relative advantages and disadvantages of biomarkers [11]
Fig. 3: Salient features of biomarkers
Fig. 4: Biomarkers applications
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